ARCT-154

Last updated

ARCT-154
Vaccine description
Target SARS-CoV-2
Vaccine type mRNA
Clinical data
Other namesLUNAR-COV19
VBC-COV19-154
Routes of
administration 		Intramuscular
Identifiers
CAS Number

ARCT-154, also known as VBC-COV19-154 in Vietnam, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics. [2] [3] For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing. The vaccine was authorised in Japan in November 2023. [4]

Contents

Medical uses

The vaccine requires two doses, the second one being administered 28 days after the first shot. [5] It is a self-amplifying mRNA vaccine. [6] [2] [7]

Manufacturing

The vaccine candidate can be made in a lyophilized powder form, [2] allowed it to be shipped and stored between 2 and 8 °C (36 and 46 °F). [8]

In August 2021, Arcturus Therapeutics entered a partnership with Vinbiocare, a unit of Vingroup to conduct clinical trials of ARCT-154 COVID-19 vaccine, developed created using Arcturus’ STARR mRNA technology, in Vietnam and establish a manufacturing facility a factory in Hòa Lạc Hi-tech Park, Hanoi, which requires an estimated investment of $200 million and has the capacity to make 200 million doses per year. [2] [9] [10] [3] It is expected that Vingroup will produce its first batches of the vaccine in early 2022. [11] Arcturus will provide to Vinbiocare access to "proprietary technologies and processes for the manufacture" of its vaccines, as well as an exclusive license to manufacture them solely for sales and use in Vietnam. [5] [2] [7] This includes all of Arcturus’ other Covid-19 vaccines such as ARCT-021 and other vaccines in the future for disease prevention in Vietnam. [10] Vinbiocare will pay $40m upfront, be responsible for technology transfer costs, and "pay for mRNA drug substance supplied by Arcturus and royalties on vaccines produced at the facility". [5] [9]


Clinical trials

Preclinical research showed that it elicits neutralizing antibodies in non-human primates against COVID-19 variants of concern, including the SARS-CoV-2 Alpha variant, Beta variant, Delta variant, and Gamma variant. [5] [7] [12]

In Singapore

On 3 August, Arcturus Therapeutics confirmed that the company had received approval for a clinical trial of ARCT-154 and another vaccine called ARCT-165 in Singapore. The Phase I-II clinical trial will evaluate the vaccines as a primary vaccination series and a booster following first dose with Pfizer–BioNTech COVID-19 vaccine. The study is being partially funded by a grant from the Singapore Government. [12] [13]

In Vietnam

The clinical trials of the vaccine in Vietnam are completely sponsored and funded by Vinbiocare, a Vingroup subsidiary. [7] [5]

On 2 August, Vinbiocare received regulatory approval to start a clinical trial of its COVID-19 vaccine candidate in Vietnam. [7] [10] The company will coordinate with the Ministry of Health to carry out Phase I-III clinical trials of VBC-COV19-154 vaccine on 21,000 adults in three phases in August 2021. [7] [2] The clinical trial Phase 1 will recruit 100 volunteers to evaluate the safety, tolerability, and initial assessment of immunogenicity of the vaccine. The clinical trial Phase 2 enrolled 300 volunteers at designated medical facilities in multiple provinces, while the third phase of human trials is expected to involve 20,600 volunteers, including phase 3a (600 volunteers) and 3b (20,000 volunteers). [10] [14] Those receiving placebo will receive active vaccine after 6 months, while all participants will be followed up for 1 year. [6]

In December 2021, the company plans to complete and submit procedures to the Ministry of Health, applying for an emergency authorization in Vietnam. [10] [2]

Phase I

The clinical trial Phase I began on 15-16 August at Hanoi Medical University. Phase I was conducted on 100 healthy volunteers randomly assigned in a ratio of 3:1, i.e. 75% of them received the ARCT-154 vaccine and 25% received a placebo. The primary objective of the phase one trial was to assess safety and immunogenicity of the vaccine. Volunteers will receive 2 doses of ARCT-154 vaccine or placebo, 28 days apart. Data of the volunteers from the first dose (day 1) to 7 days after the second dose (day 36), will be evaluated by the research team. [15] Phase I report on the safety of the ARCT-154 vaccine was approved by the Ethics Committee on September 20, 2021. Preliminary results show that the ARCT-154 vaccine is safe in healthy volunteers. [16] [17]

Phase II and III

Phase II and IIIa trials of the vaccine were carried out at the same time in Bắc Ninh, Hanoi and Long An with a total of 1,000 volunteers. The trial work in the northern localities is carried out by Hanoi Medical University and Pasteur Institute in Ho Chi Minh City in the south. In Bắc Ninh, from 20 to 23 September, the research team started recruiting volunteers and selected 338 people aged 18-65, who received the first dose from 27 to 29 September. In Long An and Hanoi, the Ministry of Health also implemented the first dose for volunteers. [17] The phase IIIa trial is expected to end on November 24, and the research team will report the results of the trial to the Ministry of Health on December 30. [17]

In Japan

A phase III trial non-inferiority trial randomized 828 participants to ARCT-154 or the Pfizer-BionTech vaccine in Japan, with results published in December 2023. [18]

Related Research Articles

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

<span class="mw-page-title-main">COVID-19 pandemic in Vietnam</span> Ongoing COVID-19 viral pandemic in Vietnam

The COVID-19 pandemic in Vietnam has resulted in 11,624,000 confirmed cases of COVID-19 and 43,206 deaths. The number of confirmed cases is the highest total in Southeast Asia, and the 13th highest in the world. Hanoi is the most affected locale with 1,649,654 confirmed cases and 1,238 deaths, followed by Ho Chi Minh City with 628,736 cases and 20,476 deaths; however, the Vietnamese Ministry of Health has estimated that the real number of cases may be four to five times higher.

<span class="mw-page-title-main">COVID-19 vaccine</span> Vaccine against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19).

<span class="mw-page-title-main">Moderna COVID-19 vaccine</span> RNA COVID-19 vaccine

The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in humans aged six months, twelve years, or eighteen years and older. It provides protection against COVID-19, which is caused by infection by the SARS-CoV-2 virus.

<span class="mw-page-title-main">Pfizer–BioNTech COVID-19 vaccine</span> Type of vaccine for humans

The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in humans to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) that encodes a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial guidance recommended a two-dose regimen, given 21 days apart; this interval was subsequently extended to up to 42 days in the United States, and up to four months in Canada.

<span class="mw-page-title-main">ZF2001</span> Vaccine against COVID-19

ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.

The following is a timeline of the COVID-19 pandemic in Vietnam.

<span class="mw-page-title-main">CureVac COVID-19 vaccine</span> Vaccine candidate against COVID-19

The CureVac COVID-19 vaccine was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). The vaccine showed inadequate results in its Phase III trials with only 47% efficacy. In October 2021 CureVac abandoned further development and production plans for CVnCoV and refocused efforts on a cooperation with GlaxoSmithKline.

<span class="mw-page-title-main">ARCT-021</span> Vaccine candidate against COVID-19

ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.

<span class="mw-page-title-main">PTX-COVID19-B</span> Vaccine candidate against SARS-CoV-2 (COVID-19)

PTX-COVID19-B is a messenger RNA (mRNA)-based COVID-19 vaccine, a vaccine for the prevention of the COVID-19 disease caused by an infection of the SARS-CoV-2 coronavirus, created by Providence Therapeutics—a private Canadian drug company co-founded by Calgary, Alberta-based businessman Brad T. Sorenson and San Francisco–based Eric Marcusson in 2013. A team of eighteen working out of Sunnybrook Research Institute in Toronto, Ontario developed PTX-COVID19-B in less than four weeks, according to the Calgary Herald. Human trials with sixty volunteers began on January 26, 2021, in Toronto.

<span class="mw-page-title-main">Abdala (vaccine)</span> Vaccine against COVID-19

Abdala, technical name CIGB-66, is a COVID-19 vaccine developed by the Center for Genetic Engineering and Biotechnology in Cuba. This candidate, named after a patriotic drama by Cuban independence hero José Martí, is a protein subunit vaccine containing COVID-derived proteins that trigger an immune response. The full results of the clinical trial have not yet been published. This candidate followed a previous one called CIGB-669 (MAMBISA).

<span class="mw-page-title-main">Nanocovax</span> Vaccine candidate against COVID-19

Nanocovax is a Vietnamese COVID-19 vaccine candidate developed by Nanogen Pharmaceutical Biotechnology JSC. It is a subunit vaccine.

<span class="mw-page-title-main">COVID-19 vaccination in Vietnam</span> Plan to immunize against COVID-19 in Vietnam

The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.

<span class="mw-page-title-main">Sanofi–Translate Bio COVID-19 vaccine</span> Vaccine candidate against COVID-19

The Sanofi–Translate Bio COVID-19 vaccine, also known as MRT5500 or VAW00001, was a COVID-19 vaccine candidate developed by Sanofi Pasteur and Translate Bio. The development was stopped in September 2021.

<span class="mw-page-title-main">Walvax COVID-19 vaccine</span> Vaccine candidate against COVID-19

AWcorna, originally termed ARCoV and also known as the Walvax COVID-19 vaccine, is an mRNA COVID-19 vaccine developed by Walvax Biotechnology, Suzhou Abogen Biosciences, and the PLA Academy of Military Science. In contrast to other mRNA COVID vaccines, such as those by Pfizer-BioNtech and Moderna, this vaccine primarily targets the Sars-CoV-2 receptor-binding domain of the spike protein, rather than the entire spike protein. It is approved for Phase III trials in China, Mexico, Indonesia, and Nepal.

<span class="mw-page-title-main">Vabiotech COVID-19 vaccine</span> Vaccine candidate against COVID-19

Vabiotech COVID-19 vaccine is a COVID-19 vaccine candidate developed by the Vaccine and Biological Production Company No. 1 (Vabiotech) in Vietnam.

<span class="mw-page-title-main">COVAX-19</span> Vaccine candidate against COVID-19

COVAX-19 is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine, in collaboration with CinnaGen, a private company with operations in the Middle East. It is under clinical trial in collaboration with the Iranian company CinnaGen.

<span class="mw-page-title-main">AdCLD-CoV19</span> Vaccine candidate against COVID-19

AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co, a company from South Korea.

<span class="mw-page-title-main">COVID-19 vaccine clinical research</span> Clinical research to establish the characteristics of COVID-19 vaccines

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness, and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:

Self-amplifying RNA (saRNA), also termed self-replicating RNA (srRNA), is a type of mRNA molecule engineered to replicate itself within host cells, enhancing protein expression and boosting the immune response, making it a promising tool for vaccines and other therapeutic applications. As a "next-generation" mRNA, saRNA is designed to achieve greater protein expression with a reduced dose compared to conventional mRNA. Unlike conventional mRNA, which has a short half-life and limited ability to express proteins for an extended time, saRNA can sustain protein expression for longer periods. saRNA are based on positive single stranded RNA viruses most commonly alphaviruses such as Venezuelan equine encephalitis virus.

References

  1. ↑ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. 1 2 3 4 5 6 7 "Vingroup collaborates with Arcturus Therapeutics to establish a manufacturing facility in Vietnam for Arcturus' mRNA Covid-19 vaccine". Yahoo! Finance . 2 August 2021.
  3. 1 2 Giang NK (2 August 2021). "Arcturus Allows Vietnam's Vingroup to Make Covid Vaccines". Bloomberg .
  4. ↑ "Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults". CSL. Retrieved 12 July 2024.
  5. 1 2 3 4 5 Arthur R (2 August 2021). "Arcturus Therapeutics lines up Phase 1/2/3 trial for next-generation mRNA COVID-19 vaccine". Biopharma Reporter.
  6. 1 2 "Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern". Business Wire . 2 August 2021.
  7. 1 2 3 4 5 6 "Arcturus to start clinical trial of COVID-19 vaccine in Vietnam". Reuters . 2 August 2021.
  8. ↑ Huynh M (2 August 2021). "Vingroup nhận chuyển giao độc quyền công nghệ sản xuất vắc xin mRNA phòng COVID-19" [Vingroup receives exclusive technology transfer for COVID-19 mRNA vaccines]. Tuổi Trẻ (in Vietnamese).
  9. 1 2 "Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus' Investigational mRNA Vaccines for COVID-19". Business Wire . 2 August 2021.
  10. 1 2 3 4 5 "Sắp thử nghiệm vaccine Covid-19 thứ ba của Việt Nam" [Vietnam set to start third Covid-19 vaccine trial]. VnExpress (in Vietnamese). 2 August 2021.
  11. ↑ Châu L (2 August 2021). "Vingroup tiếp nhận công nghệ sản xuất vắc xin Covid-19 chống lại các biến chủng mới" [Vingroup receives Covid-19 vaccine technology transfer to fight against new variants]. Thanh Niên (in Vietnamese).
  12. 1 2 "Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study". Yahoo! Finance . 3 August 2021.
  13. ↑ "Why Arcturus Therapeutics Stock Is Soaring Today". The Motley Fool . 3 August 2021.
  14. ↑ Lin T (2 August 2021). "Cho phép thử nghiệm lâm sàng vaccine COVID-19 mua công nghệ mRNA của Mỹ" [American mRNA Covid-19 vaccine candidate gets green light for trial]. Lao Động (in Vietnamese).
  15. ↑ "100 người đầu tiên sắp tiêm thử vaccine Covid thứ ba của Việt Nam". VnExpress (in Vietnamese). 14 August 2021.
  16. ↑ "Kết quả bước đầu của vaccine ARCT-154". Vietnam Government Portal. 29 September 2021.
  17. 1 2 3 "Thử nghiệm vaccine ARCT-154 giai đoạn 2 và 3a" (in Vietnamese). VnExpress. 29 September 2021. Retrieved 29 September 2021.
  18. ↑ Oda Y, Kumagai Y, Kanai M, Iwama Y, Okura I, Minamida T, et al. (April 2024). "Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial". The Lancet. Infectious Diseases. 24 (4): 351–360. doi:10.1016/S1473-3099(23)00650-3. PMID   38141632.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.